Retatrutide Phase 3 Results: What TRIUMPH-1 Shows (2026)
The first Phase 3 readout for the triple agonist is in — here’s what the topline numbers say, and what they don’t.
Abstract: Retatrutide’s Phase 3 results from TRIUMPH-1 show up to 28.3% average weight loss at 80 weeks in adults with obesity and no diabetes — the strongest data the GLP-1 class has produced so far. This guide unpacks the figures dose by dose, separates the two estimands behind the headline, explains why a triple agonist beats a dual one, and grades the evidence honestly: this is investigational, topline, not yet FDA-approved.
When Eli Lilly released the topline retatrutide Phase 3 results from TRIUMPH-1 on 21 May 2026, the number that travelled was 28.3% average body-weight loss at the 12 mg dose. For context, that is a level of weight reduction previously associated mostly with bariatric surgery — and it came from a once-weekly injection. But a press-release headline is not a peer-reviewed paper, and “up to 28.3%” hides a more useful story about doses, estimands, and what is still unknown. This article walks through what TRIUMPH-1 actually measured, how retatrutide compares to its own Phase 2 data and to tirzepatide, and where the honest caveats sit.
Retatrutide is an investigational, first-in-class triple hormone receptor agonist — it activates the GIP, GLP-1, and glucagon receptors at once. It is a research-grade compound here, not an approved medicine; everything below is framed for research and educational use only.
What TRIUMPH-1 measured
TRIUMPH-1 is the pivotal obesity trial in Lilly’s broader TRIUMPH Phase 3 programme (Giblin et al., Diabetes Obes Metab 2026). It was a randomised, double-blind, placebo-controlled study of 2,339 adults with obesity, or overweight plus at least one weight-related comorbidity, without type 2 diabetes. Participants received once-weekly subcutaneous retatrutide at 4 mg, 9 mg, or 12 mg, or placebo, over 80 weeks. All three doses met the trial’s primary and key secondary endpoints.
The “no diabetes” detail matters. Weight-loss responses to incretin drugs tend to be larger in people without diabetes than in those with it, so TRIUMPH-1 represents something close to a best-case obesity population. The companion trials — TRIUMPH-2 (obesity with type 2 diabetes) and TRIUMPH-3 (established cardiovascular disease) — are designed to test harder populations and are expected to read out later in 2026.
The headline numbers, dose by dose
Here is the topline efficacy at 80 weeks, using the treatment-regimen estimand (the more conservative measure, which counts everyone as randomised regardless of whether they stayed on the drug):
| Dose | Mean weight loss at 80 wk | Approx. pounds lost |
|---|---|---|
| Placebo | 2.2% | — |
| Retatrutide 4 mg | 19.0% | ~47 lb |
| Retatrutide 9 mg | 25.9% | ~64 lb |
| Retatrutide 12 mg | 28.3% | ~70 lb |
Two further figures fill out the picture. First, 45.3% of participants on 12 mg lost at least 30% of their body weight — the threshold long discussed as comparable to surgical outcomes. Second, the often-quoted 30.3% figure comes from a different analysis: the efficacy estimand (what happens in people who actually stay on treatment) in a study extension out to 104 weeks, among participants with a baseline BMI of 35 or higher. Same drug, different question — which is exactly why the two numbers differ and why “up to 30.3%” should never be reported as the average result. Understanding that distinction — the estimand defines what the percentage means — is the difference between reading the trial and reading the headline.
Beyond weight: the TRIUMPH-4 signals
The first Phase 3 readout in the programme was actually TRIUMPH-4 (December 2025), a trial in people with obesity and knee osteoarthritis. It reported up to 28.7% weight loss at 68 weeks alongside endpoints that go past the scale:
- a 75.8% reduction in osteoarthritis knee pain (on the WOMAC pain scale),
- roughly a 20% reduction in LDL cholesterol,
- and 72% of participants with prediabetes returning to normal glucose regulation.
These are topline sponsor-reported figures, not yet fully published, and the osteoarthritis result in particular is confounded by the mechanical benefit of carrying 70 fewer pounds. But taken together they point at the broader thesis behind the GLP-1 class — that the metabolic and anti-inflammatory effects extend well past appetite, a theme explored in how GLP-1 works for weight loss and in the 2026 cancer-risk data.
Why a triple agonist goes further
Semaglutide hits one receptor (GLP-1). Tirzepatide hits two (GLP-1 + GIP). Retatrutide adds a third — glucagon — and that third arm is the reason its weight-loss ceiling appears higher.
The intuition is counterintuitive: glucagon is the hormone that raises blood sugar, so adding a glucagon agonist to a diabetes-adjacent drug sounds backwards. The trick is balance. At the right ratio, glucagon-receptor activation increases energy expenditure and drives hepatic fat oxidation — it makes the body spend more fuel — while the GLP-1 and GIP arms suppress appetite and protect glucose control so the glucagon signal doesn’t push sugar up. The net effect is appetite suppression plus a metabolic-rate contribution, where dual agonists rely mostly on appetite alone. In mechanistic terms, the glucagon arm feeds directly into lipolysis and energy output rather than just intake reduction.
This is also why retatrutide’s GI side-effect profile matters so much to its dosing: the same potency that drives the weight loss drives dose-dependent nausea, vomiting, and diarrhoea, which is why every protocol — investigational or otherwise — uses slow titration from a low starting dose. See the retatrutide dosing guide for how that titration ladder is structured in research settings.
How Phase 3 compares to what we already knew
The prior best evidence for retatrutide was Phase 2 (Jastreboff et al., NEJM 2023), which reported about 24.2% weight loss at 48 weeks on 12 mg. TRIUMPH-1’s 28.3% at 80 weeks does two things: it confirms the Phase 2 signal at the far larger scale a Phase 3 demands, and it shows the curve had not fully plateaued at 48 weeks — more time produced more loss. That is the single most important upgrade to our knowledge base on this compound: the evidence tier moves from a mid-stage trial to a pivotal one.
Against the rest of the class, the rough hierarchy at top doses now reads: semaglutide ~15%, tirzepatide ~20–23%, retatrutide ~28%+. The caveat is that these come from separate trials with different populations and durations — there is no head-to-head Phase 3 pitting retatrutide against tirzepatide, so cross-trial comparisons are directional, not definitive. The fuller side-by-side lives in the retatrutide vs tirzepatide comparison and the retatrutide review.
What this data does not settle
Honest evidence grading is the point of this article, so the limits matter as much as the wins:
- Topline, not peer-reviewed. The 28.3% figure is from a sponsor press release corroborated by Healio, AJMC, Pharmacy Times, TCTMD and Medscape. The full data set, subgroup analyses, and adverse-event tables await publication and regulatory review.
- Two estimands, two numbers. The 28.3% (treatment-regimen) and 30.3% (efficacy, BMI ≥35, 104 weeks) answer different questions. Quoting either as “the” result without that context is misleading.
- Not FDA-approved. Retatrutide remains investigational. It is not approved for any use, and the TRIUMPH-2 (diabetes) and TRIUMPH-3 (cardiovascular) trials still need to read out.
- GI tolerability is real. Dose-dependent nausea, vomiting and diarrhoea were reported, and some analysts flagged the adverse-event profile at the top dose. Muscle loss is also a class-wide concern during rapid weight loss — the mitigation strategies are covered in how to keep muscle on a GLP-1.
- No long-term or maintenance data yet. Whether weight is regained after stopping, as with other incretins, is not answered by an 80-week trial.
FAQ
What were retatrutide’s Phase 3 results? In TRIUMPH-1, adults with obesity and no diabetes lost an average of 19.0%, 25.9%, and 28.3% of body weight at 80 weeks on 4 mg, 9 mg, and 12 mg respectively, versus 2.2% on placebo. About 45.3% of the 12 mg group lost at least 30% of their body weight.
Is retatrutide better than tirzepatide? On cross-trial comparison, top-dose retatrutide (~28%) shows greater average weight loss than top-dose tirzepatide (~20–23%), likely due to its added glucagon-receptor activity. But there is no direct head-to-head Phase 3 trial, so the comparison is indirect.
Where does the “30.3%” number come from? From a different analysis — the efficacy estimand (people who stayed on treatment) in a 104-week extension, among participants with a baseline BMI of 35 or higher. It is not the same as the 80-week average.
Is retatrutide FDA-approved? No. As of mid-2026 it is investigational and not approved for any indication. The remaining TRIUMPH trials in diabetes and cardiovascular disease are expected to read out later in 2026.
Why does retatrutide cause more nausea? Its potency and its glucagon component make GI adverse events dose-dependent. This is why research protocols titrate slowly from a low starting dose rather than starting high.
References
- Eli Lilly and Company (2026, May 21). Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1). Investor release. investor.lilly.com
- Giblin, et al. (2026). The TRIUMPH phase 3 clinical trial programme of retatrutide: design and rationale. Diabetes, Obesity and Metabolism. doi:10.1111/dom.70209
- Jastreboff, A.M. et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 389(6), 514-526. doi:10.1056/NEJMoa2301972
- Rosenstock, J. et al. (2023). Retatrutide for people with type 2 diabetes: a phase 2 trial. The Lancet, 402(10401), 529-544. doi:10.1016/S0140-6736(23)01053-X
- Coskun, T. et al. (2022). LY3437943, a novel triple GIP/GLP-1/glucagon receptor agonist. Cell Metabolism, 34(9), 1234-1247. doi:10.1016/j.cmet.2022.07.013
Research / educational use only. This article summarises investigational clinical-trial data and does not constitute medical advice or a recommendation to use any compound. Retatrutide is not FDA-approved and is not a treatment for obesity, diabetes, or any condition. Figures cited are topline, sponsor-reported, and pending peer review. Consult a qualified clinician for any health decision. — Indexa Labs Research Team